Effective treatment for de novo hepatitis B with nucleotide analogue in patients with hematological malignancies.
Yoshihide
Y
Ueda
Hiroyuki
H
Marusawa
Tatsuo
T
Ichinohe
Norimitsu
N
Kadowaki
Takashi
T
Uchiyama
Tsutomu
T
Chiba
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D002584:Cervix Uteri / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006509:Hepatitis B / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000150:complications* / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D013270:Stomach / Q000473:pathology; D014182:Transplantation, Autologous; D014750:Vincristine / Q000627:therapeutic use
D000998:Antiviral Agents; D019259:Lamivudine; C413685:entecavir; D014750:Vincristine; D006147:Guanine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone